Ir para o conteúdo principal Ir para o menu de navegação principal Ir para o rodapé
Scientific Electronic Archives
Ciências da Saúde
DOI: 10.36560/16620231733
Enviado: 2022-12-12
Publicado: 2023-05-30

Prevalence and influence of overweight and obesity on clinical and epidemiological profile of breast cancer patients in the North of Mato Grosso, Brazil: a retrospective cross-sectional study

Universidade Federal de Mato Grosso – Campus Universitário de Sinop
Universidade Federal de Mato Grosso – Campus Universitário de Sinop
Universidade Federal de Mato Grosso – Campus Universitário de Sinop
Universidade Federal de Mato Grosso – Campus Universitário de Sinop
Universidade Federal de Mato Grosso – Campus Universitário de Sinop
Universidade Federal de Mato Grosso, Campus Universitário de Sinop / Escola Técnica Estadual de Educação Profissional e Tecnológica de Sinop
Hospital Santo Antônio, Sinop
Hospital Santo Antônio, Sinop, Brazil
Universidade Federal de Mato Grosso – Campus Universitário de Sinop
Universidade Federal de Mato Grosso – Campus Universitário de Sinop
##plugins.generic.jatsParser.article.authorBio##
×

Eveline Aparecida Isquierdo Fonseca de Queiroz

  • Dr. Eveline A. I. F. Queiroz.
  • Docente de Farmacologia junto ao curso de Medicina da UFMT, Campus de Sinop.
  • Docente e Orientadora do Programa de Pos-Graduacao em Ciencias em Saude (PPGCS).
  • Núcleo de Pesquisa e Apoio Didatico em Saude (NUPADS), Instituto de Ciencias da Saude (ICS), Campus Universitario de Sinop, Universidade Federal de Mato Grosso.
Cancer, Breast cancer, Overweight, Obesity, Prognosis

Resumo

Obesity is one of the main preventable risk factors in post-menopausal breast cancer. This retrospective cross-sectional study aimed to demonstrate the clinical and epidemiological profile of breast cancer patients diagnosed in the period from 2013 to 2018 in the North of Mato Grosso, Brazil and to verify the prevalence and influence of overweight and obesity in these patients. Data were collected from patient’s medical records who were diagnosed with breast carcinoma in the Department of Oncology of Santo Antônio’s Hospital, in Sinop-MT. 196 patients were included. 99.5% were women. The majority were married, ≥50 years old (57.7%) and overweight or obese. In the overweight and obesity group the percentage of patients with invasive breast carcinoma were significantly higher when compared with eutrophic group (p=0.03). In all groups the profile of estrogen and progesterone receptors positive and HER-2 negative were more prevalent, however, the frequency of triple negative profile was higher in the overweight (7.1%) and obesity (6.3%) group when compared with control (4.3%) group, as well as the presence of hypertension and diabetes. In conclusion, it was observed a high prevalence of overweight and obesity in breast cancer patients, which contributed to modify the histological type of breast cancer (high prevalence of invasive and lobular carcinomas), increase the frequency of patients in stages 3 and 4, the percentage of triple negative profile and the frequency of other comorbidities, as hypertension and diabetes. Furthermore, metformin, an antidiabetic drug, seems to be contributing to reduce tumor development and improve the clinical profile and prognosis in diabetic breast cancer patients.

Referências

  1. AHMAD, A. Breast Cancer Metastasis and Drug Resistance. In: AHMAD, A. (org.). Advances in Experimental Medicine and Biology. 2. ed. Mobile, AL, USA: Springer US, 2019. v. 1152, p. 413–427. Available at: https://doi.org/10.1007/978-3-030-20301-6_22
  2. AKRAM, M. et al. Awareness and current knowledge of breast cancer. Biological Research, [s. l.], v. 50, n. 1, p. 1–23, 2017. Available at: https://doi.org/10.1186/s40659-017-0140-9
  3. ANGULO, M. M. et al. Cáncer de mama. Medicine - Programa de Formación Médica Continuada Acreditado, [s. l.], v. 11, n. 27, p. 1629–1640, 2013. Available at: https://doi.org/10.1016/S0304-5412(13)70517-1
  4. ARGOLO, D. F.; HUDIS, C. A.; IYENGAR, N. M. The Impact of Obesity on Breast Cancer. Current Oncology Reports, [s. l.], v. 20, n. 47, p. 2–8, 2018.
  5. AVGERINOS, K. I. et al. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism: Clinical and Experimental, [s. l.], v. 92, p. 121–135, 2019. Available at: https://doi.org/10.1016/j.metabol.2018.11.001
  6. BOYLE, P. et al. Diabetes and breast cancer risk: A meta-analysis. British Journal of Cancer, [s. l.], v. 107, n. 9, p. 1608–1617, 2012. Available at: https://doi.org/10.1038/bjc.2012.414
  7. BRAY, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, [s. l.], v. 68, n. 6, p. 394–424, 2018a. Available at: https://doi.org/10.3322/caac.21492
  8. BRAY, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, [s. l.], v. 68, n. 6, p. 394–424, 2018b. Available at: https://doi.org/10.3322/caac.21492
  9. CALLE, E. E.; KAAKS, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature reviews. Cancer, [s. l.], v. 4, n. 8, p. 579–591, 2004. Available at: https://doi.org/10.1038/nrc1408. Acesso em: 9 jun. 2020.
  10. CANCER TODAY. [S. l.], 2022. Available at: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&i. Acesso em: 21 nov. 2022.
  11. CASTANEDA, S.; CLINICS, J. S.-S. O.; 2017, undefined. Updates in the treatment of breast cancer with radiotherapy. surgonc.theclinics.com, [s. l.], [s. d.]. Available at: https://www.surgonc.theclinics.com/article/S1055-3207(17)30013-3/abstract. Acesso em: 10 ago. 2021.
  12. CHACÓN, R.; COSTANZO, M. Triple-negative breast cancer. Breast cancer research : BCR, [s. l.], v. 12 Suppl 2, n. Suppl 2, p. S3, 2010. Available at: https://doi.org/10.1186/BCR2574. Acesso em: 10 ago. 2021.
  13. CHIARADIA, A. E. F. et al. Clinical and epidemiological profile of breast cancer patients diagnosed in Sinop – MT: A descriptive study. Scientific Electronic Archives, [s. l.], v. 14, n. 3, p. 84–93, 2021. Available at: https://doi.org/10.36560/14320211327. Acesso em: 10 ago. 2021.
  14. CLAVEL, M.; SOUKOP, M.; ONCOLOGY, Y. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology, [s. l.], v. 50, p. 180–185, 1993. Available at: https://www.karger.com/Article/Abstract/227174. Acesso em: 10 ago. 2021.
  15. DENG, T. et al. Obesity, Inflammation, and Cancer. [S. l.: s. n.], 2016. ISSN 1553-4006.v. 11 Available at: https://doi.org/10.1146/annurev-pathol-012615-044359
  16. DRÃGÃNESCU, M.; TRESTIOREANU, A.; CARMOCAN, C. Hormone Therapy in Breast Cancer. Review Article Chirurgia, [s. l.], v. 112, n. 4, p. 2017, 2017. Available at: https://doi.org/10.21614/chirurgia.112.4.413. Acesso em: 10 ago. 2021.
  17. FONSECA, E. A. I. et al. Metformin reduces the stimulatory effect of obesity on in vivo Walker-256 tumor development and increases the area of tumor necrosis. Life Sciences, [s. l.], v. 88, n. 19–20, p. 846–852, 2011. Available at: https://doi.org/10.1016/j.lfs.2011.03.005. Acesso em: 22 jan. 2021.
  18. FORTNER, R. T. et al. Obesity and Breast Cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, [s. l.], v. 208, p. 43–65, 2016. Available at: https://doi.org/10.1007/978-3-319-42542-9_3. Acesso em: 22 jun. 2020.
  19. FUJII, T. et al. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA oncology, [s. l.], v. 1, n. 9, p. 1311–1318, 2015. Available at: https://doi.org/10.1001/JAMAONCOL.2015.3062. Acesso em: 19 ago. 2021.
  20. HAN, H. et al. Hypertension and breast cancer risk : a systematic review and meta- analysis. Nature Publishing Group, [s. l.], v. 20, n. 7, p. 1–9, 2017. Available at: https://doi.org/10.1038/srep44877
  21. HARBECK, N.; GNANT, M. Breast cancer. The Lancet, [s. l.], v. 389, n. 10074, p. 1134–1150, 2017. Available at: https://doi.org/10.1016/S0140-6736(16)31891-8
  22. IBGE. [S. l.], 2021a. Available at: https://cidades.ibge.gov.br/brasil/mt/sinop/historico. Acesso em: 25 jan. 2021.
  23. IBGE. [S. l.], 2021b. Available at: https://www.ibge.gov.br/cidades-e-estados/mt/sinop.html. Acesso em: 22 jan. 2021.
  24. INCA. Estimativa Câncer 2020. [S. l.: s. n.], 2019a.
  25. INCA. [S. l.], 2019b. Available at: https://www.inca.gov.br/estimativa. Acesso em: 22 jan. 2021.
  26. JIRALERSPONG, S.; GOODWIN, P. J. Obesity and breast cancer prognosis: Evidence, challenges, and opportunities. Journal of Clinical Oncology, [s. l.], v. 34, n. 35, p. 4203–4216, 2016. Available at: https://doi.org/10.1200/JCO.2016.68.4480
  27. KOPELMAN, P. G. Obesity as a medical problem. Nature, [s. l.], v. 404, n. 6778, p. 635–643, 2000. Available at: https://doi.org/10.1038/35007508
  28. LEE, K. et al. Impact of obesity on breast cancer treatment. Current obesity reports, [s. l.], v. 21, n. 5, p. 41, 2019. Available at: https://doi.org/10.1016/s1359-6349(08)70405-1
  29. LEWANDOWSKA, A. M. et al. Environmental risk factors for cancer – review paper. Annals of Agricultural and Enviromental Medicine, [s. l.], v. 26, n. 1, p. 1–7, 2019. Available at: https://doi.org/10.26444/aaem/94299
  30. LIBSON, S.; LIPPMAN, M. A review of clinical aspects of breast cancer. International Review of Psychiatry, [s. l.], v. 26, n. 1, p. 4–15, 2014. Available at: https://doi.org/10.3109/09540261.2013.852971
  31. MARTIN, S. D.; MCGEE, S. L. Metabolic reprogramming in type 2 diabetes and the development of breast cancer. Journal of Endocrinology, [s. l.], v. 237, n. 2, p. 35–46, 2018. Available at: https://doi.org/10.1530/JOE-18-0037
  32. MATTIUZZI, C.; LIPPI, G. Current Cancer Epidemiology glossary. Journal of Epidemiology and Global Health, [s. l.], v. 9, n. 4, p. 217–222, 2019.
  33. MIRANDA, V. C. et al. Exploring the role of metformin in anticancer treatments: A systematic review. Drugs of Today, [s. l.], v. 50, n. 9, p. 623–640, 2014. Available at: https://doi.org/10.1358/dot.2014.50.9.2229920
  34. NEUHOUSER, M. L. et al. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Oncology, [s. l.], v. 1, n. 5, p. 611–621, 2015. Available at: https://doi.org/10.1001/JAMAONCOL.2015.1546. Acesso em: 10 ago. 2021.
  35. PARIDA, S.; SIDDHARTH, S.; SHARMA, D. Adiponectin, obesity, and cancer: Clash of the bigwigs in health and disease. International Journal of Molecular Sciences, [s. l.], v. 20, n. 10, p. 1–27, 2019. Available at: https://doi.org/10.3390/ijms20102519
  36. PICON-RUIZ, M. et al. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA: A Cancer Journal for Clinicians, [s. l.], v. 67, n. 5, p. 378–397, 2017. Available at: https://doi.org/10.3322/caac.21405
  37. QUEIROZ, E. et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PloS one, [s. l.], v. 9, n. 5, 2014. Available at: https://doi.org/10.1371/JOURNAL.PONE.0098207. Acesso em: 7 dez. 2022.
  38. QUEIROZ, E. A. et al. Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a. Life Sciences, [s. l.], v. 121, p. 78–87, 2015. Available at: https://doi.org/10.1016/j.lfs.2014.11.028. Acesso em: 22 jan. 2021.
  39. QUEIROZ, E. A. I. F. et al. Obesidade e câncer: mecanismos envolvidos e intervenções terapêuticas. Scientific Electronic Archives, [s. l.], v. 15, n. 3, 2022. Available at: https://doi.org/10.36560/15320221522. Acesso em: 18 nov. 2022.
  40. ROJAS, K.; STUCKEY, A. Breast Cancer Epidemiology and Risk Factors. Clinical Obstetrics and Gynecology, [s. l.], v. 59, n. 4, p. 651–672, 2016. Available at: https://doi.org/10.1097/GRF.0000000000000239. Acesso em: 22 jan. 2021.
  41. SAHRA, I. Ben et al. Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Molecular Cancer Therapeutics, [s. l.], v. 9, n. 5, p. 1092–1099, 2010. Available at: https://doi.org/10.1158/1535-7163.MCT-09-1186
  42. SAMUEL, S. M. et al. Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treatment Reviews, [s. l.], v. 70, n. August, p. 98–111, 2018. Available at: https://doi.org/10.1016/j.ctrv.2018.08.004
  43. SERAVALLE, G.; GRASSI, G. Obesity and hypertension. Pharmacological Research, [s. l.], v. 122, p. 1–7, 2017. Available at: https://doi.org/10.1016/j.phrs.2017.05.013
  44. SOARES, P. B. M. et al. Características das mulheres com câncer de mama assistidas em serviços de referência do Norte de Minas Gerais. Revista Brasileira de Epidemiologia, [s. l.], v. 15, n. 3, p. 595–604, 2012. Available at: https://doi.org/10.1590/S1415-790X2012000300013. Acesso em: 25 jan. 2021.
  45. SUN, Y. S. et al. Risk factors and preventions of breast cancer. International Journal of Biological Sciences, [s. l.], v. 13, n. 11, p. 1387–1397, 2017. Available at: https://doi.org/10.7150/ijbs.21635
  46. VINEIS, P.; WILD, C. P. Global cancer patterns : causes and prevention. The Lancet, [s. l.], v. 383, n. 9916, p. 549–557, 2014. Available at: https://doi.org/10.1016/S0140-6736(13)62224-2
  47. WINTERS, S. et al. Breast Cancer Epidemiology, Prevention, and Screening. [S. l.]: Elsevier Inc., 2017. ISSN 18780814.v. 151 Available at: https://doi.org/10.1016/bs.pmbts.2017.07.002
  48. YEO, W. et al. NEPA efficacy and tolerability during (neo) adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. BMJ supportive & palliative care, [s. l.], 2020. Available at: https://doi.org/10.1136/bmjspcare-2019-002037. Acesso em: 10 ago. 2021.

Como Citar

Alves da Silva Ferreira, K., Veloso de Moura Fé, V., Paglione Balestero de Lima, V., Antunes Dias, F. ., Couto Medeiros, T. ., Albino de Queiroz, D. ., … Isquierdo Fonseca de Queiroz, E. A. (2023). Prevalence and influence of overweight and obesity on clinical and epidemiological profile of breast cancer patients in the North of Mato Grosso, Brazil: a retrospective cross-sectional study. Scientific Electronic Archives, 16(6). https://doi.org/10.36560/16620231733